Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.39 |
| ▸ | XDH | P47989 | 2/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | CLK1 | P49759 | 1/20 | 0.35 |
| ▸ | CLK2 | P49760 | 1/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.33 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22822422 | 0.82 | XDH (0.38) | XDHCLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL8513604 | 0.82 | XDH (0.38) | XDHHRH3CLK2DYRK1ACLK4 | |
| SCHEMBL586863 | 0.80 | XDH (0.38) | XDHCLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL13147938 | 0.77 | CDK4 (0.36) | PDE10ACDK4CDK6SRCMTNR1A | |
| SCHEMBL8511874 | 0.75 | XDH (0.37) | XDHCLK2DYRK1ACLK4DYRK1B | |
| SCHEMBL586909 | 0.74 | NUAK1 (0.39) | XDHSRCCTSLMTNR1A | |
| SCHEMBL579200 | 0.74 | XDH (0.41) | XDH | |
| SCHEMBL8513959 | 0.72 | ELANE (0.55) | XDH | |
| SCHEMBL8513406 | 0.72 | MTNR1A (0.40) | PDE10ACDK4SRCMTNR1AMTNR1B | |
| SCHEMBL29572866 | 0.71 | XDH (0.61) | XDHAVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-9593108-B2 | Compounds and methods for antiviral treatment | PTC THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC THERAPEUTICS, INC. (US) | 2012-05-31 | — | — | US | disclosed |
| EP-2417133-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | PTC Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010117935-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | SCHERING CORPORATION (US) | 2010-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135999-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | EIF2AK2, MAVS, ZC3HAV1 | PDE10A 3156/4885XDH 555/4885HRH3 1147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.